[go: up one dir, main page]

MX2017005884A - Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos. - Google Patents

Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.

Info

Publication number
MX2017005884A
MX2017005884A MX2017005884A MX2017005884A MX2017005884A MX 2017005884 A MX2017005884 A MX 2017005884A MX 2017005884 A MX2017005884 A MX 2017005884A MX 2017005884 A MX2017005884 A MX 2017005884A MX 2017005884 A MX2017005884 A MX 2017005884A
Authority
MX
Mexico
Prior art keywords
methods
predictors
fluid retention
treating ckd
treating
Prior art date
Application number
MX2017005884A
Other languages
English (en)
Inventor
Andress Dennis
K Kohan Donald
Coll Blai
J Lambers Heerspink Hiddo
DE ZEEUM Dick
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2017005884A publication Critical patent/MX2017005884A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a métodos para el tratamiento de la enfermedad renal crónica y la nefropatía diabética, utilizando predictores de la retención de líquidos para minimizar el riesgo de eventos adversos. Los métodos descritos son particularmente útiles en tratamientos que involucran el uso de antagonistas del receptor de endotelina, y más particularmente, atrasentán y sales farmacéuticamente aceptables del mismo.
MX2017005884A 2014-11-07 2015-11-06 Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos. MX2017005884A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462077108P 2014-11-07 2014-11-07
PCT/US2015/059456 WO2016073846A1 (en) 2014-11-07 2015-11-06 Methods of treating ckd using predictors of fluid retention

Publications (1)

Publication Number Publication Date
MX2017005884A true MX2017005884A (es) 2017-06-26

Family

ID=55909856

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005884A MX2017005884A (es) 2014-11-07 2015-11-06 Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.

Country Status (9)

Country Link
US (1) US20160128980A1 (es)
EP (1) EP3215138A4 (es)
JP (1) JP2017534634A (es)
CN (1) CN107106522A (es)
AU (1) AU2015342929A1 (es)
BR (1) BR112017009668A2 (es)
CA (1) CA2966756A1 (es)
MX (1) MX2017005884A (es)
WO (1) WO2016073846A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049234A1 (en) 2014-09-23 2016-03-31 Icahn School Of Medicine At Mount Sinai Systems and methods for treating a psychiatric disorder
SG11201907435PA (en) 2017-02-27 2019-09-27 Idorsia Pharmaceuticals Ltd Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
ES3035734T3 (en) 2017-11-30 2025-09-08 Idorsia Pharmaceuticals Ltd Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
CN116173014A (zh) 2019-12-17 2023-05-30 奇努克医疗公司 用阿曲生坦治疗IgA肾病的方法
KR20250016196A (ko) 2022-05-22 2025-02-03 이도르시아 파마슈티컬스 리미티드 고혈압의 치료를 위한 아프로시텐탄
CN118262911B (zh) * 2024-03-12 2024-08-20 广东省人民医院 一种糖尿病患者dme风险评估模型及早期筛查系统

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545920A1 (en) * 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
WO2012139866A1 (en) * 2011-04-15 2012-10-18 Universität Zürich Prorektorat Mnw Collagen hydroxylases
WO2014138738A1 (en) * 2013-03-08 2014-09-12 Abbive Inc. Methods of treating acute kidney injury

Also Published As

Publication number Publication date
CN107106522A (zh) 2017-08-29
EP3215138A4 (en) 2018-11-21
CA2966756A1 (en) 2016-05-12
WO2016073846A1 (en) 2016-05-12
AU2015342929A1 (en) 2017-05-25
US20160128980A1 (en) 2016-05-12
BR112017009668A2 (pt) 2017-12-26
JP2017534634A (ja) 2017-11-24
EP3215138A1 (en) 2017-09-13

Similar Documents

Publication Publication Date Title
MX2017005884A (es) Metodos para el tratamiento de la erc, utilizando predictores de la retencion de liquidos.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
LT3472153T (lt) Pirimidin-2-ilamino-1h-pirazolai kaip lrrk2 inhibitoriai, skirti naudoti neurodegeneracinių sutrikimų gydyme
JO3735B1 (ar) مركبات ألكين بها استبدال رباعي واستخداماتها
LT3253865T (lt) Metodai, skirti sustiprinti terapinių imuninių ląstelių veiksmingumą
EA201791884A1 (ru) Химерные антигенные рецепторы против dll3 и способы применения
EA201691683A1 (ru) Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
PH12015502275A1 (en) Therapuetic uses of empagliflozin
TR201808169T3 (tr) Rekombinant probiyotik bakteriler .
TR201902516T4 (tr) Glukagon-glp-1-gıp üçlü agonist bileşikleri.
MX375476B (es) Composición farmacéutica que comprende empagliflozina, métodos para tratamiento y sus usos.
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
PH12016501051A1 (en) Methods of treasting and preventing alloantibody driven chronic graft versus host disease
HK1243430A1 (zh) 通过施用il-6r拮抗剂治疗乾眼病的方法
GB201409936D0 (en) System, method and program for securely managing financial transactions
SG10201804034QA (en) Methods for treating hypotension
GB201902819D0 (en) Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using LGR4, LGR5 and LGR6
MX2017009281A (es) Antihistamina para usar en el tratamiento de cancer de seno.
MX2019014090A (es) Métodos para el tratamiento de la reservoritis crónica.
MX2017016533A (es) Metodo para tratar glomeruloesclerosis focal y segmentaria primaria.
NZ727147A (en) Combination therapy comprising olaratumab and doxorubicin
EA201301080A1 (ru) Применение солей 3-карбокси-n-этил-n,n-диметилпропан-1-аммония при лечении сердечно-сосудистого заболевания
MA40574A (fr) Traitement de maladies fibrotiques
NZ730759A (en) 1,2-benzothiazole compounds for the treatment of kidney disorders
Dening Japan in days of yore; v. 1